Skip to content

Company · founded 1997

Endo Pharmaceuticals (United States)

Malvern, United States · endo.com

Manage this page

Citations, last 5 years: 82
Works, last 5 years: 95
h-index: 92
Scientists listed: 4
Grants since 2016: 10

Grants received

2022–2024 · research · R44

Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers

Gail E. Sonenshein · Endo Pharmaceuticals (United States) · funded by National Institutes of Health

$1MHER2/EGFR in Cancer Research

2022–2025 · research · R44

Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers

Gail E. Sonenshein · Endo Pharmaceuticals (United States) · funded by National Institutes of Health

$1MHER2/EGFR in Cancer Research

2019–2022 · research · R43

Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers

Gail E. Sonenshein · Endo Pharmaceuticals (United States) · funded by National Institutes of Health

$300kHER2/EGFR in Cancer Research

2016–2022 · research · R44

Antibody targeting of ADAM8 for treatment of triple-negative breast cancer

Gail E. Sonenshein · Endo Pharmaceuticals (United States) · funded by National Institutes of Health

$1MHER2/EGFR in Cancer Research

2016–2018 · research · R41

Antibody targeting of ADAM8 for treatment of triple-negative breast cancer

Gail E. Sonenshein · Endo Pharmaceuticals (United States) · funded by National Institutes of Health

$50kHER2/EGFR in Cancer Research

2016–2020 · research · R44

Antibody targeting of ADAM8 for treatment of triple-negative breast cancer

Gail E. Sonenshein · Endo Pharmaceuticals (United States) · funded by National Institutes of Health

$2 084HER2/EGFR in Cancer Research

2016–2018 · research · R41

Antibody targeting of ADAM8 for treatment of triple-negative breast cancer

Gail E. Sonenshein · Endo Pharmaceuticals (United States) · funded by National Institutes of Health

$300kHER2/EGFR in Cancer Research

2016–2018 · research · R41

Antibody targeting of ADAM8 for treatment of triple-negative breast cancer

Gail E. Sonenshein · Endo Pharmaceuticals (United States) · funded by National Institutes of Health

$3 000HER2/EGFR in Cancer Research

2016–2020 · research · R44

Antibody targeting of ADAM8 for treatment of triple-negative breast cancer

Gail E. Sonenshein · Endo Pharmaceuticals (United States) · funded by National Institutes of Health

$1MHER2/EGFR in Cancer Research

2016–2018 · research · R41

Antibody targeting of ADAM8 for treatment of triple-negative breast cancer

Gail E. Sonenshein · Endo Pharmaceuticals (United States) · funded by National Institutes of Health

$63.5kHER2/EGFR in Cancer Research